Literature DB >> 29725842

Motor neuron disease of paraneoplastic origin: a rare but treatable condition.

Nicolas Mélé1, Giulia Berzero2,3, Thierry Maisonobe4, François Salachas5, Guillaume Nicolas6, Nicolas Weiss7, Guillemette Beaudonnet8, Francois Ducray9,10, Dimitri Psimaras2,10, Timothée Lenglet4,5.   

Abstract

Paraneoplastic motor neuron disorders (MND) are rare conditions; their exact clinical and electrophysiological phenotype have not been exhaustively described yet. The purpose of this study is to depict the main characteristics of paraneoplastic MND to highlight the features that may allow its diagnosis. Based on the description of eight original cases, and on the revision of 21 patients identified from a systematic review of the literature, the main features of paraneoplastic MND can be summarized as follows: (1) subacute; (2) lower motor neuron syndrome, associated or not with upper motor neuron involvement; (3) predominant asymmetric upper limb involvement; (4) presence of other non-motor neurological manifestations, including sensory neuronopathy; (5) signs of inflammation in the cerebrospinal fluid (CSF); (6) neurological improvement or stabilization after immunotherapy and tumor treatment. The diagnosis of paraneoplastic MND may be difficult because of its rarity, the absence of pathognomonic clinical features, and the frequent absence of prior tumor history. However, it is of capital importance to correctly identify patients with paraneoplastic MND, as this represents a potentially treatable condition. In the presence of subacute lower motor neuron impairment, especially when atypical clinical features for degenerative MND or other non-motor neurological manifestations are present, we recommend testing for onconeural antibodies. In the case, the search for onconeural antibodies is negative, but it exists a strong clinical suspicion for a paraneoplastic etiology; CSF analysis and total-body 18FDG-PET/CT imaging should be performed to circumstantiate diagnosis.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Cancer; Motor neuron disease; Motor neuronopathy; Paraneoplastic neurological syndrome

Mesh:

Substances:

Year:  2018        PMID: 29725842     DOI: 10.1007/s00415-018-8881-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  28 in total

Review 1.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Authors:  B R Brooks; R G Miller; M Swash; T L Munsat
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-12

Review 2.  Paraneoplastic syndromes involving the nervous system.

Authors:  Robert B Darnell; Jerome B Posner
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

3.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  Int J Surg       Date:  2010-02-18       Impact factor: 6.071

4.  Expression of Yo Antigen in a Prostatic Adenocarcinoma.

Authors:  Nicolas Rosine; Pascale Chrétien; Clovis Adam; Guillemette Beaudonnet; Adeline Not; Julien Drai; Katayoun Vahedi; Cécile Cauquil; Marie Theaudin
Journal:  Can J Neurol Sci       Date:  2017-03       Impact factor: 2.104

5.  "Non-classical" paraneoplastic neurological syndromes associated with well-characterized antineuronal antibodies as compared to "classical" syndromes - More frequent than expected.

Authors:  Benjamin Berger; Patricia Bischler; Rick Dersch; Tilman Hottenrott; Sebastian Rauer; Oliver Stich
Journal:  J Neurol Sci       Date:  2015-03-23       Impact factor: 3.181

6.  Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers.

Authors:  Bruno Giometto; Wolfgang Grisold; Roberta Vitaliani; Francesc Graus; Jérôme Honnorat; Guido Bertolini
Journal:  Arch Neurol       Date:  2010-03

7.  Recommended diagnostic criteria for paraneoplastic neurological syndromes.

Authors:  F Graus; J Y Delattre; J C Antoine; J Dalmau; B Giometto; W Grisold; J Honnorat; P Sillevis Smitt; Ch Vedeler; J J G M Verschuuren; A Vincent; R Voltz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

8.  Paraneoplastic subacute lower motor neuron syndrome associated with solid cancer.

Authors:  Annie Verschueren; Julien Gallard; José Boucraut; Jerome Honnorat; Jean Pouget; Shahram Attarian
Journal:  J Neurol Sci       Date:  2015-08-12       Impact factor: 3.181

9.  Motor neuron disease: a paraneoplastic process associated with anti-hu antibody and small-cell lung carcinoma.

Authors:  A Verma; J R Berger; S Snodgrass; C Petito
Journal:  Ann Neurol       Date:  1996-07       Impact factor: 10.422

Review 10.  Is there a paraneoplastic ALS?

Authors:  Philippe Corcia; Paul H Gordon; Jean-Philippe Camdessanche
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-10-06       Impact factor: 4.092

View more
  7 in total

1.  Cancer and motor neuron disease-causal or coincidental? Two contrasting cases.

Authors:  John Goodfellow; George Gorrie; Veronica Leach; Sameer Patel; Graham Mackay
Journal:  Neurol Sci       Date:  2019-03-06       Impact factor: 3.307

2.  Granzyme B in peripheral blood mononuclear cells as a measure of cell-mediated immune response in paraneoplastic neurological syndromes and malignancy.

Authors:  Mikołaj Piotr Zaborowski; Patrycja Stefens-Stawna; Krystyna Osztynowicz; Tomasz Piorunek; Halina Batura-Gabryel; Agnieszka Dyzmann-Sroka; Wojciech Kozubski; Ewa Nowak-Markwitz; Sławomir Michalak
Journal:  Cancer Immunol Immunother       Date:  2020-11-02       Impact factor: 6.968

3.  Clinical characteristics of patients with motor neuron disease and concurrent tumors.

Authors:  Yuan Li; Lu Chen; Nan Zhang; Dong-Sheng Fan
Journal:  Chin Med J (Engl)       Date:  2020-11-23       Impact factor: 2.628

4.  Motor Neuron Disease and Risk of Cancer: A Population-Based Cohort Study in Denmark.

Authors:  Trine Toft Sørensen; Dóra Körmendiné Farkas; Emil Zâl Bjerregaard Riahi; Vera Ehrenstein; Victor W Henderson
Journal:  Clin Epidemiol       Date:  2020-12-08       Impact factor: 4.790

5.  Nuclear depletion of RNA-binding protein ELAVL3 (HuC) in sporadic and familial amyotrophic lateral sclerosis.

Authors:  Sandra Diaz-Garcia; Vivian I Ko; Sonia Vazquez-Sanchez; Ruth Chia; Olubankole Aladesuyi Arogundade; Maria J Rodriguez; Bryan J Traynor; Don Cleveland; John Ravits
Journal:  Acta Neuropathol       Date:  2021-10-07       Impact factor: 17.088

6.  Paraneoplastic Amyotrophic Lateral Sclerosis: Case Series and Literature Review.

Authors:  Zhao Yang; Lu He; Manli Ren; Yizhou Lu; Huanyu Meng; Dou Yin; Sheng Chen; Qinming Zhou
Journal:  Brain Sci       Date:  2022-08-08

7.  Paraneoplastic Myeloneuropathies: Clinical, Oncologic, and Serologic Accompaniments.

Authors:  Shailee Shah; Rocio Vazquez Do Campo; Neeraj Kumar; Andrew McKeon; Eoin P Flanagan; Christopher Klein; Sean J Pittock; Divyanshu Dubey
Journal:  Neurology       Date:  2020-11-18       Impact factor: 9.910

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.